StockNews.AI
REGN
StockNews.AI
189 days

Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REGN

1. Regeneron faces a class action lawsuit alleging securities fraud. 2. The lawsuit claims misleading statements boosted Eylea's sales. 3. Investors could recover losses from November 2023 to October 2024. 4. False reporting may lead to violations of the False Claims Act. 5. No costs to class members for participating in the lawsuit.

4m saved
Insight
Article

FAQ

Why Bearish?

Lawsuits can negatively affect investor sentiment, similar to past cases involving regulatory scrutiny.

How important is it?

Legal issues can lead to significant market volatility and impact stock performance.

Why Short Term?

Initial negative impact likely as the lawsuit unfolds; however, long-term effects depend on lawsuit outcomes.

Related Companies

NEW YORK, Feb. 11, 2025

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit.

CLASS DEFINITION:

The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024. Follow the link below to get more information and be contacted by a member of our team:

Link to More Information

CONTACT:

REGN investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS:

The filed complaint alleges that defendants made false statements and/or concealed that:

  1. Regeneron paid credit card fees to distributors on the condition that distributors did not charge, one of the Company's primary products, Eylea customers more to use a credit card;
  2. these payments subsidized the prices that customers paid when using credit cards to purchase Eylea;
  3. as a result, Regeneron offered a price concession that lowered Eylea's selling price;
  4. because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron's price concessions provided a competitive advantage;
  5. as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales;
  6. by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act;
  7. and as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT'S NEXT?

If you suffered a loss in Regeneron during the relevant time frame, you have until March 10, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU:

If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY:

Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE

Levi & Korsinsky, LLP

Related News